Mucormycosis is an aggressive and often fatal fungal infection, posing a significant challenge in immunocompromised patients, particularly those with diabetes, cancer, or post-organ transplantation. Despite available antifungal treatments such as amphotericin B, posaconazole, and isavuconazole, mortality rates remain high, highlighting the need for early diagnosis and aggressive intervention. This review explores current therapeutic strategies, including antifungal therapy, and the critical role of surgical intervention in improving outcomes. Additionally, it examines innovative drug delivery systems, such as nanoparticle-based formulations and liposomal encapsulation, designed to enhance drug efficacy while minimizing toxicity. The recent surge in mucormycosis cases, particularly during the COVID-19 pandemic, emphasizes the urgent need for improved awareness, early detection, and optimized treatment protocols. Advancements in diagnostic techniques and emerging therapeutic approaches offer hope for better management of this deadly infection. By analyzing current trends and future directions, this article advocates for a multidisciplinary approach that combines clinical expertise with cutting-edge research. Strengthening collaborative efforts in diagnosis, treatment, and drug development is essential to reducing mortality and improving patient outcomes in this rare but lifethreatening disease.
In the realm of nanomedicine, graphene quantum dots (GQDs) stand at the forefront, offering transformative potential for cancer diagnosis and therapy. Possessing exceptional optical and electronic properties, biocompatibility, and versatile surface customization, GQDs emerge as powerful tools for advanced imaging and targeted drug delivery. Synthesized through innovative bottom-up and top-down methods, GQDs present a diverse tool for precise tailoring. Their application in cancer therapy, especially when functionalized with vitamins, proteins, peptides, and polysaccharides, showcases remarkable versatility and efficacy. These tailored drug delivery systems demonstrate not only enhanced drug effectiveness and reduced toxicity but also enable targeted cancer treatment. Ongoing research into GQD synthesis and functionalization, coupled with a deeper understanding of their interactions with biological systems, promises to further refine cancer diagnosis and therapy. The potential of GQDs as intelligent carriers holds the key to revolutionizing cancer treatment, offering renewed hope for improved patient outcomes and quality of life.
Exosomes, small extracellular vesicles involved in intercellular communication, have emerged as promising tools in cancer treatment. Their ability to transport therapeutic agents like miRNAs and proteins directly to tumour cells highlights their role in gene therapy, immunotherapy, and drug delivery. Exosomes modulate the tumour microenvironment by promoting metastasis, angiogenesis, and immune suppression, making them central to cancer pathogenesis. Recent advancements focus on engineering exosomes for targeted therapies, enhancing precision in cancer treatment while minimizing toxicity. Preclinical studies demonstrate exosomes' ability to target tumour cells and cross biological barriers, with clinical trials investigating their use as biomarkers, drug carriers, and diagnostic tools. For example, exosome-based miRNA signatures are being explored for early cancer detection, while exosomes derived from mesenchymal stem cells are tested to enhance curcumin bioavailability in rectal and lung cancer. With ongoing research and trials, exosomes hold significant potential for personalized cancer therapies, early detection, and non-invasive diagnostics.
The DeepFake tech has had a theatrical impact on the visual arts, not only the provision of creative technology, but also the question of authenticity, copyright and misinformation. The deep learning and generative adversarial networks (GANs) produce deepfakes artificial images, which are extremely harmful to art. The article discusses the DeepFake detection and management within visual art work with emphasis on the practical application of analysis through multiple-layered approaches that would assist in ensuring the presence of the digital authenticity. DeepFake was managed through three core approaches, namely AI-Based Detection Frameworks, Blockchain-Based Authentication System, and Human-AI Collaborative Review Models. The decentralized strategy was based on blockchain technology, which was the Non-Fungible Token (NFT) registration by the cryptographic hashing to authenticate the provenance and ownership of the artworks. The human-AI composite system has integrated the inspection of the specialists on the visual level with the automatic monitoring of the anomalies to increase the readability and reduce the number of false alarms. The experiment revealed that the AI-based systems, blockchain approaches, and the collusion between human beings and AI detected 92.3, 87.6 and 94.1 % of people respectively. These findings suggest that the incorporation of algorithmic intelligence, a safe check, and human knowledge can help in quite a powerful DeepFake verification and management in the field of visual arts.
The EGFR, a major receptor tyrosine kinase in the HER family, controls cell growth and division via its extracellular and intracellular tyrosine kinase domains. Ligand binding and receptor dimerization stimulate downstream pathways such as KRAS-BRAF-MEK-ERK, which are critical for cell proliferation, survival, and angiogenesis. Dysregulation of EGFR is linked to cancer development by encouraging uncontrolled cell proliferation, resistance to apoptosis, and metastases. Anti-EGFR medicines, including monoclonal antibodies (e.g., cetuximab) that prevent ligand binding and tyrosine kinase inhibitors (e.g., gefitinib), suppress abnormal EGFR signaling to slow cancer growth. Their usefulness is, however, constrained by issues, such as drug resistance, off-target effects, and limited potency in specific tumors. By using nanoparticles, including liposomes, polymeric nanoparticles, and quantum dots, for accurate drug administration, decreased systemic toxicity, and circumvention of resistance mechanisms, nanotechnologybased techniques have been developed to improve EGFR-targeted therapy. Functionalized nanoparticles improve effectiveness and make combo treatments possible by permitting regulated drug release and active targeting. These developments hold promise for addressing present constraints and offering individualized treatment choices. Comprehending EGFR signaling and using nanotechnology continue to be essential for creating more potent, focused cancer treatments.
